Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and Mechanisms

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|1|43-49

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.1, 2005-02, pp. : 43-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemosensitization by Antisense Oligonucleotides Targeting MDM2

By  

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-01 ,pp. : 51-56

Bentham Science Publishers

Access to resources Recommend Favorite

Valeriana jatamansi Constituent IVHD-valtrate As a Novel Therapeutic Agent to Human Ovarian Cancer: in vitro and in vivo Activities and Mechanisms

By  

Current Cancer Drug Targets, Vol. 13, Iss. 4, 2013-01 ,pp. : 472-483

Bentham Science Publishers

Access to resources Recommend Favorite

Stabilized Lipid Coated Lipoplexes for the Delivery of Antisense Oligonucleotides to Liver Endothelial Cells In Vitro and In Vivo

By Bartsch Martin   Weeke-Klimp Alida H.   Hoenselaar Evelien P.D.   Stuart Marc C.A.   Meijer Dirk K.F.   Scherphof Gerrit L.   Kamps Jan A.A.M.  

Journal of Drug Targeting, Vol. 12, Iss. 9-10, 2004-10 ,pp. : 613-621

Informa Healthcare

Access to resources Recommend Favorite

2'-Modified Oligonucleotides for Antisense Therapeutics

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 7, 2007-04 ,pp. : 641-649

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides

By  

Current Drug Targets, Vol. 2, Iss. 2, 2001-06 ,pp. : 167-180

Bentham Science Publishers

Access to resources Recommend Favorite